SomaLogic Overview 4-18-18v1€¦ · Our protein-based insights empower users to continuously...
Transcript of SomaLogic Overview 4-18-18v1€¦ · Our protein-based insights empower users to continuously...
© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.
Introduction
Spring 2018
1
© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.
1. We uniquely deliver meaningful and actionable health insightsacross many diseases, conditions and markets
2. These insights are derived from precise, proprietary and simultaneous measurement of 5000 proteins; every sample, every time
3. Our protein-based insights empower users to continuously optimize their personal health and wellness
2
Leading the future of healthcare
Healthcare today
3
• Focused on “sick” care• Major players try to lead, but are
fragmented• Includes payers, providers,
employers, Medicaid and Medicare, biopharma, and others
• Pay-for-service: Process and history more important than nimble response to new data
• Data types are fragmented, “noisy”
The future of healthcare
4
• Data-driven insights• Biology-based rational actions• “Root cause” analytics and
interventions• “Non-noisy” data predominates• Accessible
• Focused on personalized preventionand cures
• Features greater consumer/patient choice and control over traditional players
• Pay for outcomes/value
Technology convergence is driving the future of human health
5
Advanced big data interpretationand delivery technologies
Advanced “omics”measurement technologies
Crowded field of genomic information companies are trying to drive future healthcare
6
Genomic information is not sufficient
7
"Deg
résd
es â
ges"
, Fra
nçoi
s Geo
rgin
, 18
26. S
ourc
e: W
ikim
edia
Basically the same genome
Which “omic” delivers data-driven, highly personalized insights into real-time health?
• The proteome reflects:– dynamic “real-time” biology– current health status (response to
diet, environment, drug treatment, genetic variations, etc.)
• The genome is:– a static measurement of
potential future risk– basically the same throughout
life (“one and done”)
8
• Colored lines: Groups of protein changes in a single individual over 4 yrs.
• Black line: 900 proteins that remained stable
n=16
n=16
n=20
n=1
n=7
n=8
n=900
6/09 1/10 6/10 1/11 6/11 1/12 6/12 1/13 6/13
Conc
entr
atio
n
Time (4 years)
…other proteins change at various times
Most proteins stay constant…
Highly multiplexed proteomics-based health information will drive future healthcare
9
SomaLogic alone has the highly multiplexed proteomics technology needed to drive precision healthcare
• SomaLogic has developed the “SOMAscan®
assay,” a proprietary, scalable and CLIA-certified protein-measurement technology
• SOMAscan reproducibly measures 5,000 proteins (current version) across a wide concentration range in a single small sample volume
• SOMAscan can analyze thousands of samples a day, fully scalable
• The health-management insights derived from SOMAscan data put SomaLogic at the forefront of future healthcare information companies
10
“SomaLogic was started around a simple idea… We believed that medical diagnostics was not as useful for patients and healthcare as it had to be, and that
personalized medicine would depend on genomics and proteomics.”Larry Gold – 2015, Journal of Molecular Evolution
Access quality samples from many sources for many indications
• Pharmaceutical company collaborators– Disease knowledge, progression, recurrence– Drug efficacy, side effects– Large-scale learning collaborations, pharma-funded
• Academic collaborators– KOLs, Centers of Excellence in specific disease areas or
conditions• Major biobank collaborators
– Large cohorts with clinical outcome data that can yield insights across multiple disease areas
• 200K samples in queue for 2018, >1M by 2020
11
Sample & Clinical Dataacquisition
SomaLogic strategy
Analyze samples with SOMAscan assay
12
• SOMAscan analysis• 175,000 samples total through 2017• 200,000 samples in 2018• >1 million samples by 2020• Primary sample types are blood and
urine• 5,000 protein data points per sample,
all captured in proprietary Knowledge Base
Sample & Clinical Dataacquisition
SomaLogic strategy
Build proprietary massive “Knowledge Base” of protein and related data
13
SOMAscan Platform
“Knowledge Base”
• Information includes:• All SOMAscan-based protein
analyses and all related outcome data
• 1 billion protein measurements and related data by Q42018
• 5 billion by 2020• Continuous learning with new
samples (prospective and retrospective)
Sample & Clinical Dataacquisition
SomaLogic strategy
Deploy powerful computational tools to extract and validate insights from Knowledge Base
14
Extract Validated Insights
• Insights• Derived from proprietary computational algorithms• Actionable insights to guide subsequent health
decisions (medical, lifestyle, etc.)
SOMAscan Platform
“Knowledge Base”
Sample & Clinical Dataacquisition
SomaLogic strategy
Engage world-class collaborative “Test Beds” to establish clinical impact of insights
15
Apply to Health
Management (Test Beds)
• Health systems use insights to guide and assess interventions• Establish evidence of clinical impact for global marketing• Identify new product opportunities• First Test Bed: Leeds UK (NHS); four additional in negotiation
Extract Validated Insights
SOMAscan Platform
“Knowledge Base”
Sample & Clinical Dataacquisition
SomaLogic strategy
Commercialize validated products with clinical impact in large market segments
16
Commercialize in three sectors:• Health Systems• Employer Wellness Management• Consumer Health
Apply to Health
Management (Test Beds)
Extract Validated Insights
SOMAscan Platform
“Knowledge Base”
Sample & Clinical Dataacquisition
SomaLogic strategy
Expand Knowledge Base with continuous learning for finding new insights
17
• Linking SOMAscan data with EMR and person-reported outcomes yields new insights under continuous learning system
Continuouslearning
Commercialize in three sectors:• Health Systems• Employer Wellness Management• Consumer Health
Apply to Health
Management (Test Beds)
Extract Validated Insights
SOMAscan Platform
“Knowledge Base”
Sample & Clinical Dataacquisition
SomaLogic strategy
SOMAscan-based insights in the pipeline: Consumer/lifestyle
– Nutritional status– Lean muscle mass– Physical activity– Physical fitness– Response to glucose– Intra-abdominal fat– Lean muscle mass– Bone strength– Smoking impact– Smoking type– Alcohol impact
– Metabolic rate– Molecular BMI– Weight-loss predictions– Intermittent fasting benefit
prediction– Biological age– Diet response prediction– Social deprivation– Exceptional aging– Diabetes lifestyle intervention– Lifespan
18
We are developing a “proteomic mimic” for each of these phenotypes
SOMAscan-based insights in the pipeline: Medical/health systems
Death – probability
MI – probability
Stroke – probability
Heart failure – probability
Heart failure subphenotypeand prognosis
Hospital readmission after MI
PCSK9 drug response +/-HIV
Statin pharmacology
CV treatment benefit prediction
Drug toxicity – heart
Drug toxicity – muscle
Angiogram result
Statin response prediction
Diabetes status
Diabetes probability of developing
Diabetic complications
Bariatric surgery response
Liver fat
Liver inflammation
Liver fibrosis
NASH prognosis
Kidney function
Kidney prognosis
Cancer – early detection:
– Breast
– Colon
– Lung
– Prostate
– Rectum
– Melanoma
– Lymphoma
– Endometrium
– Pancreas
– Kidney
– Liver
Cancer – susceptibility:
– Breast
– Colon
– Lung
– Prostate
– Rectum
– Melanoma
– Lymphoma
– Endometrium
– Pancreas
– Kidney
– Liver
19
First product bundles: Cardiometabolic insights
20
Incident diabetes, cardiovascular risk, kidney prognosis, liver prognosis
Lean muscle mass, fitness, nutrition, metabolism, smoking, alcohol, insulin resistance
1. Relate intensity of intervention to risks2. Choose lifestyle changes most likely to
drive risk
Example: How do I prevent type 2 diabetes onset in a middle-aged overweight person with borderline HBA1c?
Using the cardiometabolic insight bundles to guide impactful health decisions
Define health decision(s) to be
enabled
Quantify relevant medical risks
using SOMAscan
Personalize with causal and/or
actionable insights
Guide intervention and monitor impact
21
Go-to-market steps and timing for cardiometabolic insight bundle
22
Additional insight bundles around other diseases and conditionsare in development throughout!
4Q17 1Q18 2Q18 3Q18 4Q18 2Q191Q19
• Cardiometabolicbundles identified as first products
• Samples acquired
• Engaged Leeds Test bed• Others in negotiation
• Prepare bundles for delivery (product development, ops, marketing)
• Deliver to Test bed(s), evaluate clinical impact
• Initiate formal commercialization of cardiometabolicinsight bundles
ABOUT SOMALOGIC
23
About• Founded in 2000 by Larry Gold, PhD, in Boulder, CO
• $600M total invested ($150M cash on balance sheet, $40M debt)
• $365M in equity
• $235M in non-dilutive funding
• 200+ employees
• >550 issued and pending patents
• World-class strategic partners:
24
Board of Directors and Advisors
25
• Larry Gold, Founder & ChairmanSynergen, NeXagen, NeXstar
• Charles M. LillisFormer Chairman and CEO, Media One Group, Inc.; Co-founder and Managing Partner, LoneTreeCapital
• Jessica MathewsFormer President, Carnegie Endowment forInternational Peace, PhD in Mol. Biology
• Terry L. RandallPresident-CEO, Heritage Capital, LLC
• Alister (Al) W. Reynolds, CEOFormer SVP of US Operations, Quest Diagnostics
• Takayuki ShiratsuchiOperating Officer, General Manager of Basic Research, Otsuka Pharmaceuticals
• Jun WangFounder and CEO of iCarbonX,former CEO and Chairman of BGI
• Sir Marc FeldmannEmeritus Professor, University of Oxford, UK
• Peter GanzProfessor, UCSF School of Medicine
• David LawrenceFormer Chairman & CEO, Kaiser Permanente
• Sir Simon LovestoneProfessor, University of Oxford
• Craig MundiePresident, Mundie & Associates; Former Chief Research and Strategy Officer, Microsoft
• Russell RayFormer Vice Chair and Managing Director of Healthcare Investment Banking, Stifel
• Elio RiboliDirector, School of Public Health, Imperial College, London
• John Stuelpnagel Executive Chairman, Ariosa Diagnostics; Chairman, 10x Genomics; Founder and former CEO and COO, Illumina
Board Advisors
Experienced leadership team
26
Alister (Al) W. ReynoldsChief Executive Officer
Matt NorkunasChief Financial Officer
Nebojsa JanjicChief Science Officer
Stephen WilliamsChief Medical Officer
Melody HarrisChief Legal Counsel
Alan WilliamsChief Development and Operations
Mark MessenbaughChief Corp Strategy & Development
Fintan SteeleChief Communications and Culture
© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.
1. We uniquely deliver meaningful and actionable health insightsacross many diseases, conditions and markets
2. These insights are derived from precise, proprietary and simultaneous measurement of 5000 proteins, every sample every time
3. Our protein-based insights empower users to continuously optimize their personal health and wellness
27
Leading the future of healthcare
© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc. 28
© 2016 SomaLogic, Inc.© 2018 SomaLogic, Inc.
Backup slides: SOMAmers and SOMAscan
29
SOMAMERS AND SOMASCAN
30
Measuring the proteome: The challenge
31
From Baker et al. Genome Medicine 2012, 4:63
Mas
s spe
ctro
met
ry = ELISA (antibodies)
SOMAmer reagents:The heart of SomaLogic’s technology
32
• Slow Off-rate Modified Aptamers (SOMAmers) –A “next generation” of specific protein binding reagents
• Made from single-stranded DNA with “protein-like” side chains on specific bases
• Can be made to bind specifically to virtuallyany type of protein
Platelet-derived growth factor (dimer)
Nerve growth factor (dimer) Interleukin-6
The SOMAscan assay:Changing a protein measurement challenge
into a DNA measurement solution
33
• Combines thousands of different SOMAmer reagents to measure thousands of proteins in a small volume of biological sample
• Measures relative protein concentrations via DNA measurement of their binding SOMAmer partners
• Delivers unmatched specificity, sensitivity, dynamic range, reproducibility, scalability and speed
SOMAscan assay (1)
34
SOMAmers are pre-immobilized to beads
Proteins (sample) introduced into each well
Proteins bind to the SOMAmers
SOMAscan assay (2)
35
Proteins are biotinylated The photocleavable link is broken by exposure to
ultraviolet light
SOMAscan assay (3)
36
Non-specific complexes fall apart quickly
Specific complexes stay together (slow off-rate)
Second immobilization step on new beads
Unbound SOMAmers washed away
SOMAscan assay (4)
37
SOMAmers eluted off the complexes
# SOMAmers = # protein complexes
DNA SOMAmers hybridized to custom array,
Fluorescence = # SOMAmers
SOMAscan assay (5)
• Hybridization on custom Agilent arrays contributes to high dynamic range and excellent precision
• Every protein has its own standard curve
• 10 randomly placed spots averaged per protein
• A protein signal has been changed into a DNA signal
38